JP2024520897A5 - - Google Patents
Info
- Publication number
- JP2024520897A5 JP2024520897A5 JP2023569774A JP2023569774A JP2024520897A5 JP 2024520897 A5 JP2024520897 A5 JP 2024520897A5 JP 2023569774 A JP2023569774 A JP 2023569774A JP 2023569774 A JP2023569774 A JP 2023569774A JP 2024520897 A5 JP2024520897 A5 JP 2024520897A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- crystal
- pharmaceutical composition
- ray powder
- crystals
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163188833P | 2021-05-14 | 2021-05-14 | |
| US63/188,833 | 2021-05-14 | ||
| PCT/US2022/029289 WO2022241278A1 (en) | 2021-05-14 | 2022-05-13 | Solid forms of a modulator of hemoglobin |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026078723A Division JP2026129958A (ja) | 2021-05-14 | 2026-05-08 | ヘモグロビン調節因子の固体形態 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024520897A JP2024520897A (ja) | 2024-05-27 |
| JP2024520897A5 true JP2024520897A5 (cg-RX-API-DMAC7.html) | 2025-05-01 |
Family
ID=82020064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023569774A Pending JP2024520897A (ja) | 2021-05-14 | 2022-05-13 | ヘモグロビン調節因子の固体形態 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11851424B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4337659A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024520897A (cg-RX-API-DMAC7.html) |
| KR (1) | KR102968809B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN117337285A (cg-RX-API-DMAC7.html) |
| AR (1) | AR126649A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022273787B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023021606A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3219786A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023012156A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202311254A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022241278A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA202309517B (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2024007064A (es) * | 2021-12-10 | 2024-06-20 | Global Blood Therapeutics Inc | Metodos de administracion de un modulador de hemoglobina. |
| EP4727555A1 (en) * | 2023-06-13 | 2026-04-22 | Global Blood Therapeutics, Inc. | (s)-2-hydroxy-6-((4-(2-(2-hydroxyethyl)nicotinoyl)morpholin-3-yl)methoxy)benzaldehyd for use in the treatment of sickle cell disease |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US4432987A (en) * | 1982-04-23 | 1984-02-21 | Pfizer Inc. | Crystalline benzenesulfonate salts of sultamicillin |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| JP6426694B2 (ja) * | 2013-03-15 | 2018-11-21 | グローバル ブラッド セラピューティクス インコーポレイテッド | ヘモグロビンの修飾のための化合物及びその使用 |
| PT3880654T (pt) * | 2018-11-19 | 2022-04-08 | Global Blood Therapeutics Inc | Compostos de 2-formil-3-hidroxifeniloximetil capazes de modular hemoglobina |
| AR126648A1 (es) * | 2021-05-14 | 2023-11-01 | Global Blood Therapeutics Inc | Métodos para hacer un modulador de hemoglobina |
| MX2024007064A (es) * | 2021-12-10 | 2024-06-20 | Global Blood Therapeutics Inc | Metodos de administracion de un modulador de hemoglobina. |
-
2022
- 2022-05-13 BR BR112023021606A patent/BR112023021606A2/pt unknown
- 2022-05-13 KR KR1020237043235A patent/KR102968809B1/ko active Active
- 2022-05-13 EP EP22729906.2A patent/EP4337659A1/en active Pending
- 2022-05-13 CN CN202280035091.5A patent/CN117337285A/zh active Pending
- 2022-05-13 AR ARP220101301A patent/AR126649A1/es not_active Application Discontinuation
- 2022-05-13 MX MX2023012156A patent/MX2023012156A/es unknown
- 2022-05-13 WO PCT/US2022/029289 patent/WO2022241278A1/en not_active Ceased
- 2022-05-13 AU AU2022273787A patent/AU2022273787B2/en active Active
- 2022-05-13 US US17/744,537 patent/US11851424B2/en active Active
- 2022-05-13 JP JP2023569774A patent/JP2024520897A/ja active Pending
- 2022-05-13 CA CA3219786A patent/CA3219786A1/en active Pending
- 2022-05-13 TW TW111118076A patent/TW202311254A/zh unknown
-
2023
- 2023-10-11 ZA ZA2023/09517A patent/ZA202309517B/en unknown
- 2023-11-01 US US18/499,491 patent/US12473277B2/en active Active